Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.
Department of Urology, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.
Int J Mol Sci. 2023 Jan 4;24(2):964. doi: 10.3390/ijms24020964.
Bladder cancer (BCa) is associated with significant morbidity, with development linked to environmental, lifestyle, and genetic causes. Recurrence presents a significant issue and is managed in the clinical setting with intravesical chemotherapy or immunotherapy. In order to address challenges such as a limited supply of BCG and identifying cases likely to recur, it would be advantageous to use molecular biomarkers to determine likelihood of recurrence and treatment response. Here, we review microRNAs (miRNAs) that have shown promise as predictors of BCa recurrence. MiRNAs are also discussed in the context of predicting resistance or susceptibility to BCa treatment.
膀胱癌（BCa）与显著的发病率相关，其发生与环境、生活方式和遗传原因有关。复发是一个重大问题，在临床实践中通过膀胱内化疗或免疫疗法来进行管理。为了解决卡介苗供应有限和确定可能复发的病例等挑战，使用分子生物标志物来确定复发的可能性和治疗反应将是有利的。在这里，我们回顾了作为预测膀胱癌复发的有希望的miRNAs（microRNAs）。还讨论了 miRNA 在预测膀胱癌治疗的耐药性或敏感性方面的作用。
